IMPORTANCE Inflammation is critical in the development of atherosclerosis. Psoriasis is a chronic inflammatory skin disease that is associated with increased vascular inflammation by 18 fluorodeoxyglucose positron emission tomography/computed tomography in vivo and future cardiovascular events. It provides a human model to understand the effect of treating inflammation in a target organ (eg, the skin) on vascular diseases.
P soriasis is a chronic inflammatory skin disease that affects an estimated 3% of the US adult population. Psoriasis, especially when it is severe, is an independent risk factor for myocardial infarction, 1 stroke, 2 and overall cardiovascular mortality. 3 Moreover, vascular inflammation by 18 fluorodeoxyglucose positron emission tomography/computed tomography ( 18 FDG PET/CT) is associated with psoriasis skin disease severity, 4 further suggesting shared mechanisms between remote inflammation in the skin and presence of vascular disease. Given the association with early cardiovascular events, psoriasis provides a reliable human model to study the longitudinal impact of modulating target organ inflammation (eg, skin) on vascular inflammation. Vascular inflammation by 18 FDG PET/CT is an important biomarker of cardiovascular risk. 5 Aortic vascular inflammation is associated with inflammatory biomarkers in the serum, 6 marks the distribution of atherosclerotic plaques with highrisk morphological features in carotid arteries 7 and coronary arteries, 8 and is predictive of future cardiovascular events. 5 Additionally, vascular inflammation is highly sensitive to modulation of risk factors with preventive strategies such as statin therapy 9 and therapeutic lifestyle changes, 10 which are known to mitigate cardiovascular risk. Thus, using vascular inflammation by 18 FDG PET/CT as a primary outcome we hypothesized that (1) improvement in psoriasis severity would be associated with improvement in vascular inflammation at 1 year and (2) initiation of antitumor necrosis factor (TNF) therapy would lead to a reduction in vascular inflammation at 1 year.
Methods
A total of 115 consecutive patients with psoriasis recruited from January 1, 2013, to October 31, 2016, participated in an ongoing case-cohort study to understand the association between psoriasis and cardiometabolic diseases ( Figure 1) . A study health care professional confirmed the onset and duration of psoriasis and assessed psoriasis severity using the Psoriasis Area and Severity Index (PASI) score, which combines the severity of lesions and the area affected into a single score, considering erythema, induration, and desquamation within each lesion. Previous psoriasis literature has established that the degree of PASI score response defined as greater than 50% improvement as well as greater than 75% improvement is clinically significant and denotes meaningful improvement. 11 The institutional review board at the US National Institutes of Health approved the study protocol. All participants provided written informed consent and received financial compensation. Patients were required to have a formal diagnosis of plaque psoriasis for study inclusion. Patients were excluded if they had any comorbid condition known to promote cardiovascular disease or systemic inflammation, such as clinically diagnosed cardiovascular disease, uncontrolled hypertension, internal malignancy within 5 years, human immunodeficiency virus, active infection within the past 72 hours of baseline, and major surgery within 3 months.
All patients underwent
18
FDG PET/CT scans at baseline and at 1 year. All scans were read in a blinded fashion to patient characteristics and visit dates. Images were analyzed using a dedicated PET/CT analysis program (Extended Brilliance Workspace; Phillips Healthcare) to quantify vascular inflammation measured as target-to-background ratio. 4 The primary outcome for our study was change in aortic vascular inflammation at 1 year (eAppendix in the Supplement). Summary statistics are presented. Multivariable linear regression analyses were performed to evaluate the association between longitudinal changes in vascular inflammation and psoriasis severity. Statistical analyses were performed using STATA version 12 (StataCorp). We hypothesized that a 5-point Findings This cohort study found that improvement in skin disease severity is associated with an improvement in aortic vascular inflammation beyond cardiovascular risk factors, which was greater in patients with more improvement in skin disease severity. Furthermore, this association was stronger in those initiated with anti-tumor necrosis factor therapy.
Meaning These findings suggest that alleviating inflammation at remote sites in the body (eg, skin) has beneficial effect on vascular inflammation at 1 year, a finding that may have important implications in other inflammatory disease states. change in PASI score would lead to a 0.1 change in target-tobackground ratio, with an SD of 0.1, thus requiring a group of 50 patients to have 90% power to test the association of change in psoriasis severity with change in aortic vascular inflammation. Data were analyzed in November 2016. dL; P = .003; to convert to millimoles per liter, multiply by 0.0259) without any change in the proportion of patients taking statins. Furthermore, high-sensitivity C-reactive protein level was reduced at 1 year (median, 1.8 mg/L; IQR, 0.7-3.8, vs 1.3 mg/L; IQR, 0.6-3.2; P = .02; to convert to nanomolers per liter, multiply by 9.524). Moreover, psoriasis severity improved significantly at follow-up by 33% (P < .001) with increased use of systemic or biologic anti-inflammatory therapies at 1 year (39% vs 60%; P < .001), which was accompanied by a 6% improvement in vascular inflammation (mean [SD] target-tobackground ratio, 1.91 [0.29] vs 1.79 [0.22]; P < .001) (Table and Figure 2 ). No sex-or race-based interaction was found in vascular inflammation comparison over 1 year.
Results

Characteristics of the Study Group Over 1-Year Follow-up
Association of Psoriasis Skin Inflammation and Vascular Inflammation Beyond Traditional Risk Factors
Psoriasis severity was associated with vascular inflammation at baseline (β = 0.20; 95% CI, 0.018-0.379; P = .03). At 1 year, improvement in psoriasis severity was associated with an improvement in vascular inflammation (β = 0.23; 95% CI, 0.051-0.417; P = .01) ( Figure 3A) , which remained significant beyond traditional cardiovascular risk factors, body mass index, high-sensitivity C-reactive protein, statin use, and use of systemic or biologic psoriasis therapy (β = 0.19; 95% CI, 0.012-0.375; P = .03) ( Figure 3B and eTable 1 in the Supplement). Furthermore, sensitivity analyses after removing those taking any form of systemic or biologic therapy found consistent results (β = 0.22; 95% CI, 0.041-0.404; P = .03). Finally, there was a significant 11% reduction in vascular inflammation for those with greater than 75% reduction in psoriasis severity (mean [SD], 2.02 [0.36] to 1.79 [0.20]; P < .003), which was associated with improvement in psoriasis severity beyond adjustment for traditional risk factors (β = 0.57; 95% CI, 0.100-1.049; P = .04).
Anti-TNF Therapy, Psoriasis Severity, and Aortic Vascular Inflammation Over 1 Year in Severe Psoriasis
In patients with severe psoriasis who were eligible for biological therapy, anti-TNF therapy was initiated and patients were followed up for 1 year (n = 17). Patients were middle-aged (mean [SD] age, 48.6 [14.6] years), male predominant (59%), and at low cardiovascular risk by Framingham risk score (median, 3; IQR, 1-6), and they had characteristics similar to the entire sample (eTable 2 in the Supplement). At 1 year, the cohort had a reduction in psoriasis severity by 67% (median, 9; IQR, 6-15, to median, 3; IQR, 2-4; P = .002). This reduction in psoriasis severity was associated with a reduction in vascular inflammation of 6% (mean [ 
Discussion
Using a longitudinal case-cohort study design, we demonstrated that (1) when psoriasis skin disease severity improved over 1 year, there was a reduction in vascular inflammation independent of cardiovascular risk factors and (2) initiation of TNF inhibitor therapy in patients with severe treatmentnaive psoriasis led to successful clearance of severe skin disease associated with a significant improvement in vascular inflammation.
Atherosclerosis Prior studies have shown that systemic or biologic treatment of psoriasis was associated with reduced vascular disease in psoriasis, 16 demonstrating an important role for inflammation in cardiovascular disease. Furthermore, small studies using novel vascular imaging modalities showed that treatment of psoriasis with anti-TNF as well as anti-interleukin 12/23 therapies reduced vascular inflammation and reduced progression of coronary artery disease as assessed by coronary artery calcium score. 15,16 Indeed, our findings-that reduction in skin disease severity, the target organ associated with inflammation in psoriasis, is associated with reduction in vascular inflammation-further support this concept that quelling remote target organ inflammation may improve vascular diseases. Furthermore, our findings that initiation of biologic therapy with anti-TNF agents leads to pronounced improvement in vascular inflammation beyond traditional cardiovascular risk factors denote that modifying the magnitude of remote inflammation imparts benefits toward overall cardiovascular risk by direct as well as indirect effects. Statins are currently the most validated cardiovascular risk-modifying agents and have been shown to reduce vascular inflammation in dose-dependent fashion. 9 In this study, we demonstrated that approximately 33% improvement in psoriasis severity was associated with a 6% decrease in vascular inflammation in the entire cohort. This reduction is, to a similar extent, as seen following low-dose statin therapy, 9 which suggests that reducing remote skin disease severity may have short-term effects by reducing vascular inflammation comparable with low-dose statin therapy.
Limitations
Our study has certain limitations. This was an observational study; therefore, it is subject to potential for confounding including residual confounding secondary to adjustment for cohort-level changes. We did not have uniform therapy throughout the cohort. Moreover, the use of anti-TNF agents was open-label, nonrandomized, and in a small sample. Finally, we did not examine cardiovascular events but instead used vascular inflammation to understand modulation on cardiovascular disease risk. While these data strengthen the hypothesis of inflammation reduction leading to cardiovascular disease mitigation, they do not alone prove causality. Hence, future studies should attempt to characterize the shared mechanistic links involved in psoriasis and atherosclerosis, and they should try to assess how biologic therapies may modulate them. To overcome our observational study design, an ongoing randomized clinical trial will examine the effect of anti-TNF treatment with adalimumab on both skin disease and vascular inflammation at 12 weeks and 52 weeks (the Vascular Inflammation in Psoriasis-Extension Trial, NCT01866592) compared with placebo.
Conclusions
We found that improvement in target organ inflammation (eg, the skin) modulated vascular inflammation. Furthermore, initiating anti-TNF treatment had favorable impact on both skin clearance and vascular inflammation. Collectively, these findings suggest that alleviating remote skin inflammation may have positive effects on vascular inflammation at 1 year, similar to the effect of low-dose statin therapy. 
95% CI Fitted values Individual values
Improvement in psoriasis skin disease severity is associated with improvement in vascular inflammation beyond traditional cardiovascular risk factors at 1 year: in all patients with psoriasis in the cohort (n = 115), skin disease improvement was associated with reduction in vascular inflammation in unadjusted (A) and adjusted (B) analyses. Improvement in psoriasis skin disease severity is associated with improvement in vascular inflammation beyond traditional cardiovascular risk factors at 1 year: in a subcohort of biologically naive patients with psoriasis, who were initiated with anti-tumor necrosis factor (TNF) therapy (n = 17), skin disease improvement was associated with reduction in vascular inflammation in unadjusted (C) and adjusted (D) analyses. Change in psoriasis severity = psoriasis severity at baseline − psoriasis severity at 1 year. Change in target-to-background ratio = target-to-background ratio at 1 year − target-tobackground ratio at baseline.
eAppendix. Methods
Study Population
Our study included psoriasis patients recruited from January 2013 to October 2016. Data obtained from the baseline and 1-year follow-up visits of the first 115 consecutively recruited patients are reported. A study provider confirmed the onset, duration of psoriasis, and assessed psoriasis severity using the psoriasis area severity index score and body surface area (BSA). Clinical parameters including blood pressure, height and weight were ascertained during clinical visits. Laboratory parameters including fasting blood glucose, fasting lipid panel, white blood count with differential, and systemic inflammatory markers including high-sensitivity C-reactive protein (hsCRP) and erythrocyte sedimentation rate (ESR) were evaluated in a certified clinical laboratory. Data for all psoriasis patients under the cohort study at National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH) were obtained under a protocol titled Psoriasis, Atherosclerosis and Cardiometabolic Disease Initiative (PACI).
Inclusion/Exclusion criteria
To be included in the study, psoriasis patients were required to have a formal diagnosis of plaque psoriasis confirmed by a dermatologist. Patients were excluded if they had any comorbid condition known to promote cardiovascular disease or systemic inflammation, such as known cardiovascular disease, uncontrolled hypertension, internal malignancy within 5 years, human immunodeficiency virus, active infection within the past 72 hours of baseline, and major surgery within 3 months. Patients were eligible for initiating anti-tumor necrosis factor (TNF) therapy if they met the following criteria: 1) if they were biologic treatment naïve defined as follows: either a patient who has never received any biologic therapy or patient whose last biologic therapy dose was > 6 months ago; 2) patient, who upon entry into the study, had body surface area > 10% covered with psoriasis plaques.
Study/Ethical Approval
Study approval was obtained from the Institutional Review Board (IRB) of the NHLBI, NIH in accordance with the principles of Declaration of Helsinki. All guidelines for good clinical practice and those set forth by the NIH Radiation Safety Commission and in the Belmont Report (National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research) were followed. All study participants in the cohort provided written informed consent. All the participants were adequately compensated.
Primary Outcome
The primary outcome for our study was the change in the aortic vascular inflammation by 18 fluorodeoxyglucose positron emission tomography computed tomography ( 18 FDG PET/CT) from baseline to 1 year. 18 FDG PET/CT scans were analyzed to derive target-to-background ratio values to quantify vascular inflammation by previously published, and validated methods 1 . Change in psoriasis area severity index score was calculated from baseline to 1 year. The proportion of patients reaching 75% improvement in psoriasis area severity index score (psoriasis area severity index score 75) and 50% improvement in psoriasis area severity index score (psoriasis area severity index score 50) at 1 year was also evaluated 2 . Strengthening the reporting of observational studies in epidemiology 3 guidelines were followed for reporting the findings.
FDG PET/CT Image Acquisition and Analysis
Patients underwent
18 FDG PET/CT scans following overnight fast. Images were obtained approximately 60 minutes after administration of a 10mCi dose of 18 FDG. All scans were completed using a 64 slice scanner (Siemens Biograph mCT PET/CT 64 slice scanner, Malvern, PA, USA) with 1.5mm axial slices of the aorta obtained. We analyzed the uptake of 18 FDG within the aorta using a dedicated PET/CT image analysis program (Extended Brilliance Workspace, Phillips Healthcare, Andover, MA, USA) to measure vascular inflammation calculated as target-to-background ratio.
1 All scans were read in a blinded fashion to patient characteristics and visit dates.
Covariates
Baseline treatment for the cohort was defined by up to 12 months of any of the following therapy before inclusion in the study: systemic or biologic therapy (steroids, methotrexate, adalimumab, etanercept, and ustekinumab), statins, psoralen plus ultraviolet A (PUVA) or ultraviolet B (UVB), and topical treatments. Patients were asked to complete survey-based questionnaires regarding smoking, previous cardiovascular disease, family history of cardiovascular disease, and previous established diagnoses of hypertension and diabetes. Patient responses were then investigated and confirmed by interview with the a study health care professional. Cardiovascular disease included acute coronary syndrome comprising both MI and unstable angina pectoris, angina pectoris, cerebrovascular event, transient ischemic attack, peripheral vascular disease and revascularization procedures that comprised of coronary artery bypass grafting and percutaneous interventional procedures. Diabetes and hypertension were defined either by an established diagnosis or by use of glucose lowering and blood pressure lowering drugs, respectively. Exercise was defined as a self-reported categorical variable at their respective visits.
Statistical Analysis
Summary statistics were presented as means with standard deviation (S.D.) for normally distributed variables, medians and interquartile range (IQR) for non-normally distributed continuous variables and frequencies for categorical variables. Normality was assessed by skewness and kurtosis. Parametric variables were compared between groups at baseline and 1 year using paired t-test while Wilcoxon signed rank test was performed for non-parametric variables. Dichotomous variable comparisons were performed using Pearson's 2 test. We conducted multivariable linear regression analyses to evaluate the association of change in vascular inflammation versus change in psoriasis area severity index score. These analyses were adjusted for age, sex, and traditional cardiovascular risk assessed by Framingham 
